Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services to organizations engaged in genomics research and the development of personalized medicines, announces the introduction of its cell free DNA (cfDNA) HDx™ Reference Standards. The new Reference Standards support the development and optimization of cfDNA assays, which are emerging as an important tool for non-invasive liquid biopsies.
Horizon’s cfDNA Reference Standards enable researchers to demonstrate the performance of their cfDNA assays by providing a reproducible, consistent and reliable source of reference material for their development and evaluation.
Created from engineered cell lines, cfDNA Reference Standards are available in both singleplex and multiplex format with cancer-relevant mutations including BRAF, EGFR, KRAS, NRAS, and PIK3CA. These Reference Standards consist of human genomic DNA fragmented to 160 bp, representative of plasma-derived cfDNA, and are provided as a set of precisely defined allelic frequencies from as low as ...
